Fintel reports that on March 21, 2025, Benchmark initiated coverage of Kamada (NasdaqGS:KMDA) with a Buy recommendation.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Takeda Pharmaceutical has a robust drug discovery pipeline to meet future clinical demand. Check out the upside and downside ...

Earnings Per Share (TTM) A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding. Market Capitalization Reflects the total ...

M&T Bank Corp lowered its position in Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) by 10.0% in the 4th ...

Baidu, Inc. (NASDAQ: BIDU and HKEX: 9888), a leading AI company with strong Internet foundation, today launched its latest foundation models, including native multimodal foundation model ERNIE 4.5 ...

Due to hemophilia A patients switching to newer treatments, Takeda Pharmaceuticals is discontinuing both Hemofil M and Recombinate globally.

In this article, we are going to take a look at where Takeda Pharmaceutical Company Limited (NYSE:TAK) stands against the other pharma stocks. Healthcare, which includes numerous businesses that offer ...

Takeda’s revamped R&D strategy means the drugmaker’s oncology leaders are prioritizing work in tumors across thoracic, ...

Fast Company's annual list of the World's Most Innovative Companies spotlights organizations across various industries that are driving meaningful change through groundbreaking ideas and ...